Oaktree Acquisition III Life Sciences holds extraordinary general meeting
OACC•Shareholders approved extending Oaktree Acquisition III Life Sciences’ business combination deadline from October 25 to November 25, 2026, with optional monthly extensions through May 25, 2027. Holders redeemed 11,331,102 Class A ordinary shares for approximately $122.44 million.
1. Extension approved
At an October 23, 2026, extraordinary general meeting, shareholders approved extending the business combination deadline from October 25 to November 25, 2026, and authorized optional monthly extensions at the sponsor’s request through May 25, 2027. The adjournment proposal was not put to a vote because the extension proposal had sufficient support.
2. Redemptions exercised
Holders exercised redemption rights on 11,331,102 Class A ordinary shares at approximately $10.805 each, totaling approximately $122.44 million.
